NORDIC LYMPHOMA GROUP

             PLENARY MEETING OCTOBER 26-27, 2006

                             Radisson Hotel, Lillehammer, Norway

www.lillehammerhotel.no

 

Dear colleagues and representatives from the sponsors participating in the meeting"

 

It is a pleasure to welcome you to the annual Nordic Lymphoma Group plenary meeting which this year is located to the site of the Olympic Winter Games in 1994, Lillehammer. We are confident that you will find the facilities at Lillehammer Radisson SAS Hotel suitable for the occasion. The program is broadly in line with those of the previous years. We are particularly happy to announce the invited speaker this year, Michele Ghielmini, who will focus on maintenance therapy with rituximab in follicular lymphomas. Furthermore, we look forward to hear Lena Specht educate us regarding the use of radiotherapy in lymphoma today. This year we introduce a new session: Free paper presentation on on-going lymphoma research, and as the last years we also have an “interesting cases-session”.

 

This year we will have a three-days meeting with more time to informal talks and social activities. The programme includes a guided visit to Maihaugen harbouring a beautiful collection of old buildings in Norway.

 

A special NLG bus will depart from the airport at 10.00 o’clock. Please check in for the bus at a desk in the arrival hall. The bus returns from Lillehammer Saturday 13.30 and arrive in the airport about 1 hour later.

 

There is also train-connection from Gardemoen airport leaving at the following time points for Lillehammer Thursday 25th Oct.: 08.33, 09.05, 10.05, 11.05. The train trip takes 1 h 50 min.

The hotel is located few minutes on foot from the train station, but taxis will also be available.

 

Trains are leaving from Lillehammer to the airport at the following time points Sat 27th Oct:

11.10, 12.57, 13.15, 15.12. Information is available at the web site www.nsb.no

 

For the Coordinating group of the Nordic Lymphoma Group:

 

Harald Holte, Bjørn Østenstad, Mikael Eriksson

NLG Plenary meeting, Lillehammer October 25 – 27 2007

 

Agenda:

 

Thursday October 25

 

Morning   Working Group meetings (may be started at Wednesday afternoon/evening)

11.00-12.00 Registration, check in

12.00-13.00 Lunch

13.00-13.15 Meeting opens (HH, ME)

13.15-14.00 Educational lecture: Role of radiotherapy in lymphoma today, Lena Specht  14.00-14.30 Working group: Large B-cell lymphoma

14.30-15.00 Working group: Indolent lymphoma

15.00-15.30 Coffee/Tea

15.30-16.00 Working group: Mantle cell lymphoma

16.00-16.30 Working group: T-cell lymphoma

16.30-17.00 Working group: CNS lymphoma

17.00-17.30 Working group: Hodgkin’s lymphoma

18.30            Refreshments

19.00            Dinner

 

Friday October 26

 

08.00-09.00 Breakfast

09.00-10.00 National lymphoma registries – how far have we reached?

                     Presentation by the Staging/Epidemiology working group

10.00-10.30 Working group: Pathology

10.30-11.00 Coffee/Tea

11.00-12.30 Guest lecturer:

                     Michele Ghielmini: Maintenance treatment in follicular lymphoma

12.30-13.30 Lunch

13.30-16.30 Excursion in the surroundings; coffee/tea included

16.30-18.00 Free paper presentation on ongoing lymphoma research

                     Chairman: Francesco d´Amore

18.30            Refreshments

19.00            Dinner; social evening

 

Saturday October 27

 

08.00-09.00 Breakfast

09.00-10.00 Business meeting (closed for industry)

10.00-10.30 Coffee/Tea

10.30-12.00 “Interesting cases”-session

                     Chairman: Bjørn Østenstad

12.00-12.30 Summing-up session, change of chairman, and closing of the meeting

12.30            Lunch

 

 

Working Groups October 2007.

 

Coordinating Group:

Sweden: Mikael Eriksson (chairman), Lund, Eva Kimby, Stockholm.

Denmark: Francesco d'Amore, Århus, Christian Geisler, Copenhagen (treasurer)

Finland: Tuula Lehtinen, Tampere, Esa Jantunen, Kuopio.

Norway: Harald Holte (vice-chairman, Oslo, Bjørn Østenstad, Ullevaal.

Webmaster: Thomas Relander, Lund (thomas.relander@med.lu.se)

Working Groups

Chairman, members

Projects, active/ upcoming protocols

 

Design, Year of activation

Paraclinical

 

 

 

 

Staging/

Epidemiology

Eva Cavallin-Ståhl, Lund

Bjarne Egelund, Odense

Stein Kvaløy, Oslo

Tuula Lehtinen,Tampere

·          Clinical staging guidelines 1997

(see homepage)

·          Registration: Nordic lymphoma registry

 

Pathology

Christer Sundström, Uppsala

Elisabeth Ralfkiær, Copenh.

Jan Delabie, Oslo

Marja-Liisa Karjalainen-Lindsberg, Helsinki

·          Pathology-guidelines 1999 (see homepage)

 

Clinical

 

 

 

 

Large B-cell lymphoma

Harald Holte, Oslo

Øystein Fluge, Bergen

Mikael Eriksson, Lund

Magnus Björkholm, St.holm

Anne Bukh, Aalborg

Lars Møller Pedersen, Herlev

Sirpa Leppa, Helsinki

Sirkku Jyrkkiö, Tampere

·          R-CHOEP-14 + CNS prophylaxis (NLG-LBC –04)

 

·          PET-scan in large-cell lymphoma

·          Phase-II, 2004 ongoing

 

 

·          Phase-II, 2005 ongoing

 

CNS lymphoma

Elisa Pulczynski, Århus

Martin Erlanson, Umeå

Unn Merethe Fagerli, Trondheim

Outi Kuittinen, Oulu

·          Treatment of primary CNS lymphoma without radiotherapy

       

·          Phase-II, 2007 ongoing

 

Hodgkin’s Lymphoma

Gunilla Enblad, Uppsala

Lena Specht, Copenhagen

T.Turpenniemi-Hujanen, Oulu

A. Fossa, Oslo

·          Early-stage Hodgkin: A long-term study of efficacy and toxicity

·          Advanced (Stage III-IV) Hodgkin: BEACOPP vs ABVD (with EORTC)

·          Phase-II, 1999 ongoing

 

·          Phase-III, 2003 ongoing

 

Mantle cell lymphoma

Chr. Geisler, Copenhagen

Erkki Elonen, Helsinki

Anna Laurell, Uppsala

Arne Kolstad, Oslo

·          MCL2: Maintenance part

·          MCL-3 protocol: BEAM + Zevalin before ASCT. Maintenance

·          Intergroup Study: MCL in the elderly: R-CHOP vs R-FC, è

        MNT w. Rituximab of PegIntron

·          Maintenance ongoing

·          Phase-II 2004

 

 

·          Phase-III ongoing (Denmark)

 

 

Indolent

(Low-grade) lymphomas

Eva Kimby, Huddinge

Peter Brown, Copenhagen

Tuula Lehtinen, Tampere

Bjørn Østenstad, Oslo

Francesco D’Amore, Århus

·          ML 16865: Rituximab +/- Interferon in follicular lymphoma

·          Biology and prognostic factors:Transformation (Tissue arrays, immunostaining, cytogenetics and FISH)

·          Phase-III, 2003, ongoing

 

 

·          2004

 

Peripheral T-cell NHL:

Francesco D’Amore, Århus

Thomas Relander, Lund

Grete Lauritzen, Oslo

Esa Jantunen, Kuopio

Jan Delabie, Oslo

Elisabeth Ralfkiær, CPH

T-01: Autologous transplant as primary treatment of peripheral T-cell NHL.

 

T-02: International intergroup trial CHOP-14 x6 + ASCT vs A-CHOP-14x6 + ASCT (ACT-1, younger) and CHOP-14x6 vs. A-CHOP-14x6 (ACT-2, elderly)

Phase-II, 2002 ongoing

 

 

 

Phase III, 2007 activated

 

 

 

NOTES

NOTES